Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab Plus Chemotherapy for Advanced or Recurrent Non-Squamous NSCLC With EGFR-TKI Resistance
NCT02139579Phase 2Unknown
- Sponsor
- Sun Yat-sen University
- Start
- May 2014
- Primary completion
- Dec 2015
- Modality
- Monoclonal Antibodies
01
Overview
Phase 2, open-label, single-arm trial of bevacizumab in non-small cell lung cancer (NSCLC), sponsored by Sun Yat-sen University. Primary endpoint: Tumor Response based on RECIST 1.1 at 8 weeks. Status: unknown.
02
Drugs
bevacizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02139579.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02139579.